Dr. Yazan Migdady, MD

Dr. Migdady practices at Cancer Center at the Village in Wyoming, Michigan.

Dr. Migdady's NPI, 1306157458, was assigned on June 23, 2010. Dr. Migdady graduated from Jordan University of Science and Technology FOM in 2007. Dr. Migdady holds Colorado license 72189.

Dr. Migdady's primary practice is Cancer Center at the Village, at 985 Gezon SW Pkwy, Wyoming, MI 49509 in Kent County. The practice phone is (616) 252-8100.

Dr. Migdady's primary practice is Cancer Center at the Village in Wyoming, Michigan. Dr. Migdady is also affiliated with University of Michigan Health-West Hospital. The medical group on file is Trinity Health Medical Group. Dmand AI also links Dr. Migdady to 2 more hospitals, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Migdady practices, 4 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Migdady's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Migdady is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Migdady's licenses on file in 8 states: Colorado, California, Nebraska, Oregon, Washington, Wyoming, Florida and Rhode Island.

Dmand AI lists purpura and thrombocytopenia among the conditions Dr. Migdady treats.

CMS data shows 5,942 Medicare services from Dr. Migdady across 11 procedure codes in 2024, for 140 Medicare patients. Medicare paid $237,853 for them.

CMS counts 140 Medicare patients who saw Dr. Migdady in 2024. The largest group is 65 to 74, with 80 patients. 75% of them have high blood pressure, and 65% have high cholesterol. 12% are also on Medicaid. Their average risk score is 3.02, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Migdady's median patient age at 64, with 51% women.

In 2024, Dr. Migdady wrote 139 Medicare Part D claims for 20 patients. 75% of them were for generic drugs. CMS names the drug for 31 of them, across 1 drug with 11 or more claims each, at $555 in total drug cost. In 2023, CMS named 42 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 99 out of 100 for Dr. Migdady for performance year 2024, reported through an alternative payment model (APM). Dr. Migdady accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Migdady as offering telehealth.

Dmand AI links 21 papers to Dr. Migdady, published from 2011 to 2024. 2018 was the busiest year, with 4. The most frequent topics are Leukemia, Myeloid, Acute, Myelodysplastic Syndromes and Hematopoietic Stem Cell Transplantation. Dr. Migdady has published most often in Blood Adv. Dr. Migdady's most frequent co-authors are Sally Arai, MD, Asiri Saumya Ediriwickrema, MD and Bachir J. Sakr, MD.

CMS Open Payments shows 27 general payments to Dr. Migdady from 15 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 66% of the total. Syndax Pharmaceuticals, Inc. paid the most, $5,237.

Dr. Migdady graduated from Jordan University of Science and Technology FOM in 2007.

Dr. Migdady is in network with 17 carriers, including Aetna, United Healthcare and Cigna. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.